Koers Tekmira Pharmaceuticals Corporation Toronto S.E.
Aandelen
TKM
CA87911B2093
Farmaceutische producten
Omzet 2024 * | 11,97 mln. 8,75 mln. 8,16 mln. | Omzet 2025 * | 12,49 mln. 9,14 mln. 8,51 mln. | Marktkapitalisatie | 690 mln. 505 mln. 471 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -122 mln. -89,26 mln. -83,16 mln. | Nettowinst (verlies) 2025 * | -145 mln. -106 mln. -98,83 mln. | EV/omzet 2024 * | 57,7 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 55,3 x |
K/w-verhouding 2024 * |
-6,07
x | K/w-verhouding 2025 * |
-5,11
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 76,66% |
Recentste transcriptie over Tekmira Pharmaceuticals Corporation
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 49 | 01-07-14 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 11-06-18 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 68 | 01-12-14 | |
James Meyers
BRD | Director/Board Member | 58 | 23-10-18 |
Daniel Burgess
BRD | Director/Board Member | 62 | 23-03-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,79% | 87,06 mld. | |
+2,76% | 40,25 mld. | |
-17,49% | 31,09 mld. | |
+55,20% | 24,74 mld. | |
-13,13% | 15,91 mld. | |
-9,12% | 11,96 mld. | |
-15,45% | 11,92 mld. | |
-42,56% | 11,61 mld. | |
+5,24% | 8,73 mld. |